AQP4 and nervous system disorder: NMOSD has been established as a distinct neurological disorder upon the discovery of anti-AQP4 antibodies, and a new treatment era has finally dawned after the EMA approval of targeted therapies—satralizumab, inebilizumab, eculizumab and ravulizumab [1].